We found for
Learnings from the Assessments of Entrectinib and Larotrectinib: Health Technology Assessment Challenges Associated with Tumour-Agnostic Therapies
![Learnings from the Assessments of Entrectinib and Larotrectinib: Health Technology Assessment Challenges Associated with Tumour-Agnostic Therapies](https://www.ohe.org/wp-content/uploads/2023/01/Cancer_WellcomeCollection_landscape.jpg)
The Case of Risperidone: Assessing the Life-cycle Value of Second-Generation Antipsychotics in Sweden and the UK
![Risperidone Cover Page](https://www.ohe.org/wp-content/uploads/2019/07/Risperidone-Cover-Page.jpg)